Big Beat for Gilead on Rising Sovaldi Revenue

July 23 (Bloomberg) -- Gilead Sciences, maker of the hepatitis C pill Sovaldi, doubled its sales forecast for the year on better-than-estimated revenue from the blockbuster pill. Bloomberg’s Olivia Sterns reports on “Street Smart.” (Source: Bloomberg)
Will the ECB QE Actually Work?
51:56 - Bloomberg’s Lisa Abramowicz and Carl Riccadona discuss ECB President Mario Draghi’s version of quantitative easing. They speak with Bloomberg’s Alix Steel on “Street Smart.” (Source: Bloomberg)
  • Energy Companies Sell Record $14.5B Debt
  • Investors `Pricing-In' Fed Rate Increase: Clarida Says
  • Croft Says Sanctions a `Danger' to Russian Oil Projects